Clinical Trials Browser

INDUSTRY × lenvatinib × 1 year × Clear all

NCT05775159 2026-04-17

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Phase 2 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT07405164 2026-04-17

MK-6482-043

Phase 3 Recruiting

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT04164199 2026-04-14

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Phase 3 Active not recruiting

Advanced Malignancies

NCT03486873 2026-04-13

MK-3475-587

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

NCT04938817 2026-04-13

KEYNOTE-B98

Phase 1/2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT04305054 2026-04-08

KEYMAKER-U02

Phase 1/2 Active not recruiting

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT05301842 2026-04-07

EMERALD-3

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04039607 2026-04-06

CheckMate 9DW

Phase 3 Active not recruiting

732 enrolled 3 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT04199104 2026-03-27

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

Phase 3 Completed

511 enrolled 20 charts

Squamous Cell Carcinoma of Head and Neck

NCT05024214 2026-03-25

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Phase 1/2 Recruiting

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular

NCT06858813 2026-03-25

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

Phase 1 Recruiting

Gastrointestinal

Liver Neoplasms

NCT04008797 2026-03-24

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Phase 1/2 Active not recruiting

GastrointestinalGynecologic

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05319730 2026-03-20

MK-3475-06B

Phase 1/2 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT03517449 2026-03-19

MK-3475-775

Phase 3 Completed

827 enrolled 34 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT06036836 2026-03-19

MK-4280A-010

Phase 2 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT04977453 2026-03-17

Keynote B59

Phase 1/2 Recruiting

GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Phase 1/2 Recruiting

BreastGynecologicThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05523323 2026-03-13

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension

Phase 3 Completed

112 enrolled 16 charts

Squamous Cell Carcinoma of Head and Neck

NCT03573960 2026-03-06

A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

Phase 4 Completed

Thyroid Neoplasms

NCT04586231 2026-03-05

MK-6482-011

Phase 3 Active not recruiting

Carcinoma, Renal Cell

NCT02811861 2026-02-23

CLEAR

Phase 3 Active not recruiting

1,069 enrolled 12 charts 2 FDA

Carcinoma, Renal Cell

NCT03829332 2026-02-19

LEAP-007

Phase 3 Completed

623 enrolled 26 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02861573 2026-02-17

KEYNOTE-365

Phase 1/2 Recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT04626479 2026-02-12

MK-3475-03A

Phase 1/2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT03820986 2026-02-09

LEAP-003

Phase 3 Completed

674 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT03713593 2026-02-05

LEAP-002

Phase 3 Completed

794 enrolled 30 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT03829319 2026-02-05

LEAP-006

Phase 3 Completed

761 enrolled 31 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03898180 2026-02-05

LEAP-011

Phase 3 Completed

505 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT04776148 2026-02-05

MK-7902-017

Phase 3 Completed

563 enrolled 32 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT03884101 2026-02-02

LEAP-001

Phase 3 Completed

842 enrolled 25 charts

Endometrial Neoplasms

NCT05081180 2026-01-23

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

Phase 1 Active not recruiting

Neoplasms, Central Nervous System Neoplasms

NCT07081633 2025-12-30

TREMENDOUS-2

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04889118 2025-12-23

LEAP-003

Phase 3 Completed

131 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT05030506 2025-12-18

MK-6482-010

Phase 1 Active not recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04246177 2025-12-17

LEAP-012

Phase 3 Active not recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT05342636 2025-12-17

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Phase 1/2 Completed

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04949256 2025-12-15

MK-7902-014

Phase 3 Active not recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT07282509 2025-12-15

Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer

Phase 1/2 Not yet recruiting

Gastrointestinal

Advanced Hepatocellular Carcinoma (HCC)

NCT05077215 2025-12-08

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

Phase 3 Not yet recruiting

Advanced Endometrial Cancer

NCT05106127 2025-12-08

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

Phase 2 Not yet recruiting

Advanced Endometrial Cancer

NCT04428151 2025-12-04

LEAP-009

Phase 2 Completed

408 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT04704219 2025-12-03

KEYNOTE-B61

Phase 2 Completed

160 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04865289 2025-12-02

LEAP-001

Phase 3 Completed

130 enrolled 24 charts

Endometrial Neoplasms

NCT03797326 2025-11-17

LEAP-005

Phase 2 Completed

611 enrolled 27 charts

BreastCNSGastrointestinalGynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT06962787 2025-11-17

A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer

Phase 2 Recruiting

Kidney Neoplasms

NCT05899049 2025-11-10

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04700072 2025-10-28

KEYMAKER-U02

Phase 1/2 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT05091346 2025-10-24

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

Phase 1/2 Completed

89 enrolled 24 charts

DermatologicGastrointestinal

Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms

NCT05033522 2025-10-23

ALIVE

Phase 2/3 Suspended

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03564691 2025-10-07

MK-4830-001

Phase 1 Completed

Neoplasms